🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: UMEC 62.5 mcg via ELLIPTA

Found 15 matching trials

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients

PHASE4

The primary objective of this study is to assess the effect of umeclidinium...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-07-14

Trial ID

NCT02799784

Treatments Being Tested

UMEC/VI TIO/OLO Albuterol/salbutamol

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

PHASE2

This study is conducted to evaluate the effects of UMEC 62.5 microgram (mcg...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-01-25

Trial ID

NCT03012061

Treatments Being Tested

Placebo UMEC Fluticasone Furoate Albuterol/salbutamol

Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

N/A

The main purpose of the study is to assess the burden of illness for, COPD ...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-05-31

Trial ID

NCT03543176

Treatments Being Tested

UMEC/VI FLUT/SAL CAT mMRC Ellipta Diskus

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

COPD is characterized by an airflow limitation, which is not fully reversib...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-06-16

Trial ID

NCT03034915

Treatments Being Tested

UMEC/VI 62.5/25 mcg via ELLIPTA UMEC 62.5 mcg via ELLIPTA Salmeterol 50 mcg via DISKUS Placebo via ELLIPTA Placebo via DISKUS

A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

PHASE3

Despite availability of treatments and published guidelines, subjects may h...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-06-22

Trial ID

NCT03184987

Treatments Being Tested

FF/UMEC/VI 100/62.5/25 mcg FF/UMEC/VI 200/62.5/25 mcg Salbutamol ACQ-7

A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The primary purpose of this study is to assess the equivalence of closed tr...

Status

Withdrawn

Location

GSK Investigational Site

Start Date

2016-06

Trial ID

NCT02731846

Treatments Being Tested

Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg Fluticasone furoate 100 mcg + Vilanterol 25 mcg Umeclidinium 62.5 mcg Placebo ELLIPTA inhaler Albuterol/Salbutamol

VENTURI (VENTilation Using Respiratory Imaging)

PHASE2

The purpose of the study is to enroll participants with uncontrolled asthma...

Status

Recruiting

Location

The University of Alabama at Birmingham

Start Date

2026-03-15

Trial ID

NCT07282886

Treatments Being Tested

Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder

Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma

PHASE3

Asthma is a common, chronic respiratory disease affecting 1-18 percent of t...

Status

Withdrawn

Location

Multiple Locations

Start Date

2019-01-18

Trial ID

NCT03376932

Treatments Being Tested

FF/UMEC/VI FP/SAL Tiotropium Albuterol/salbutamol ELLIPTA DPI DISKUS DPI RESPIMAT inhaler Metered Dose Inhaler Connected Inhaler System

Previous Next